Week in Review: Cellular Biomedicine of China to Reverse Merger in U.S.  
1/7/2013 11:15:01 AM

by Richard Daverman, PhD

January 5, 2013 -- Cellular Biomedicine Group, a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group of the US; Guangzhou BeBetter Medicine signed a collaborative research agreement with Taiwan's PharmaEngine to develop oncology drugs; Tianjin KingYork Group and Innovata of Hong Kong formed an inhaled drug JV that will target asthma; and Sichuan Kelun Pharma paid $135 million to purchase a 12.3% stake in Lijun International Pharma. More details….

Stock Symbols: (OTCQB: EBIG) (TWO: 4162) (SHE: 002422) (HK: 2005)